Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Early morning hyperglycemia is sometimes called the “dawn phenomenon.” Left untreated, it can drive poorer outcomes. How can ...

28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...

insulins. When entering a drug such as Lantus or Novolog, a pop-up box notes, “Your drug has a generic” that may cost less. In the case of insulin, if the generic is covered, it won’t cost ...

has guaranteed that Wyoming residents not enrolled in government healthcare programs can buy insulin products for $35 each month for the next five years. The settlement announced by Attorney ...

It has been reported with insulin Lispro (Eli Lilly, Indianapolis, Indiana, USA) and insulin Glargine (Sanofi-Aventis, Paris, France). To our knowledge, this is one of the first reports of lipoatrophy ...

In July 2003. the company launched Lantus, the worlds first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.In the year 2004 ...